Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

This is a multi-center, single-arm study to investigate the efficacy and safety of liposomal irinotecan+5-FU/LV+ bevacizumab as second-line therapy in metastatic colorectal cancer in Chinese population.

Trial Details

NCT ID

NCT06184698

Phase

PHASE2

Sponsor

Hebei Medical University Fourth Hospital

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

liposomal irinotecan
5-FU
LV
Bevacizumab

Locations (sample)

Shijiazhuang, Hebei, China|38.04139,114.47861

Key Eligibility Criteria

Age: 18-75 years old.
Histologically or cytologically proven colon or rectum adenocarcinoma.
Confirmed as unresectable metastatic disease through radiological examination.
At least one measurable lesion (according to RECIST v1.1).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →